AMGEN INC is 118.2x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($183.41 B vs $1.55 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TSHA | AMGN |
|---|---|---|
| Market cap | $1.55 B | $183.41 B |
| US-listed rank | #2294 | #79 |
| Revenue (latest FY) | $9.77M | $36.75B |
| Net income (latest FY) | -$109.00M | $7.71B |
| Net margin | -1115.3% | 21.0% |
| P/E (trailing FY) | - | 23.8 |
| SEC filings | 386 | 1,011 |
AMGEN INC is 118.2x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($183.41 B vs $1.55 B).
In their latest fiscal years, Taysha Gene Therapies, Inc. reported $9.77M in revenue while AMGEN INC reported $36.75B.
Full pages: Taysha Gene Therapies, Inc. and AMGEN INC, or browse the full rankings.